UNSPSC 51384527: Ibuprofen piconol

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B0F91K5U4N, chemically known as propionic acid, 2-(p-isobutylphenyl)-, 2-pyridylmethyl ester but more generally known as ibuprofen piconol, which bears US NIH Compound Identifier 3673. European Medicines Agency schedules Ibuprofen piconol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14175MIG.

Most nations, for tariff and trade purposes, schedule ibuprofen piconol under HS 29163990 and SITC 51379. As of Q4 2014, IBUPROFEN PICONOL remains US FDA's Preferred Term for this commodity. Ibuprofen piconol bears US NLM identifiers UMLS ID C0071068 and NCI Concept Code C80556. SMILES: CC(C)CC1CCC(CC1)C(C)C(=O)OCC2CCCCN2.

UNSPSC 51384527 Ibuprofen piconol is a Commodity code that captures individual pharmaceutical active ingredients and formulations procured by state and local health agencies, though recent solicitations under this code show a mismatch between the nominal scope and actual buying activity. The three most recent opportunities posted under or near this code involve naloxone procurement, a direct-to-manufacturer pharmacy initiative, and multi-source generic pharmaceuticals through a cooperative purchasing vehicle — none of which are ibuprofen-specific. Issuing bodies include county health departments (Seminole County, Florida), state health commissions (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). The scope of work across recent solicitations spans emergency-response medications (naloxone), generic pharmaceutical supply chains, and OTC product distribution to public health facilities, reflecting a broader demand for direct pharmaceutical sourcing and cost management rather than single-ingredient procurement.

Geographic activity appears concentrated in Florida, Texas, and the Upper Midwest (Minnesota and Oregon through MMCAP). Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment capabilities; and MMCAP's RFP S1070000015802 (posted January 20, 2026, responses due March 26, 2026) establishing multi-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers with July 1, 2026 implementation. The mismatch between the ibuprofen piconol code designation and the naloxone, direct-to-manufacturer, and generic-pharmaceutical focus of posted solicitations suggests that this code may see limited relevant recent activity aligned with its nominal scope.